Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 10;12(11):1886.
doi: 10.3390/jpm12111886.

COVID-19 Impact on Chronic Myeloid Leukemia Patients

Dana Raluca Arbore  1 , Simona Maria Galdean  2 , Delia Dima  2 , Ioana Rus  2 , David Kegyes  1   3 , Raluca Geanina Ababei  2 , Daniela Dragancea  2 , Radu Andrei Tomai  2 , Adrian Pavel Trifa  1   2 , Ciprian Tomuleasa  1   2   3
Affiliations

COVID-19 Impact on Chronic Myeloid Leukemia Patients

Dana Raluca Arbore et al. J Pers Med. .

Abstract

(1) Background: Chronic myeloid leukemia (CML) is a blood dyscrasia that accounts for about 20% of all leukemia cases. Tyrosine kinase inhibitors (TKIs) are used as first line treatment of CML. The 2019 SARS-CoV-2 outbreak raised new concerns for CML patients, such as whether CML increases the risk of contracting COVID-19, whether TKIs increase that risk, whether these drugs are safe to use during the infection, and whether any other hematologic parameters influence infection outcomes. (2) Methods: In our study we addressed these intriguing questions by using a retrospective analysis of 51 CML patients treated at the Ion Chiricuta Cancer Center, Cluj-Napoca, Romania. Furthermore, we investigated the effects of currently approved COVID-19 vaccines in our CML patients treated with tyrosine kinase inhibitors. (3) Results: Our results have shown that hemoglobin level upon diagnosis of CML has been the only hematologic parameter correlated to the risk of contracting COVID-19 in our CML patients. (4) Conclusions: TKI treatment did not negatively influence COVID-19 risk or the response to the vaccine in our patients. The safety profile of the currently approved COVID-19 vaccines was similar to that of the general population.

Keywords: COVID-19; COVID-19 vaccine; SARS-Cov-2; chronic myeloid leukemia; tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Asif M., Hussain A., Wali A., Ahmed N., Ali I., Iqbal Z., Amir M., Shafiq M., Rasool M. Molecular, Cytogenetic, and Hematological Analysis of Chronic Myeloid Leukemia Patients and Discovery of Two Novel Translocations. Anal. Cell. Pathol. 2021;2021:4909012. doi: 10.1155/2021/4909012. - DOI - PMC - PubMed
    1. Bower H., Björkholm M., Dickman P.W., Höglund M., Lambert P.C., Andersson T.M.L. Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016;34:2851–2857. doi: 10.1200/JCO.2015.66.2866. - DOI - PubMed
    1. Moisoiu V., Teodorescu P., Parajdi L., Pasca S., Zdrenghea M., Dima D., Precup R., Tomuleasa C., Soverini S. Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology. Front. Oncol. 2019;23:863. doi: 10.3389/fonc.2019.00863. - DOI - PMC - PubMed
    1. Hochhaus A., Saussele S., Rosti G., Mahon F.-X., Janssen J.J.W.M., Hjorth-Hansen H., Richter J., Buske C. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2017;28((Suppl. S4)):iv41–iv51. doi: 10.1093/annonc/mdx219. - DOI - PubMed
    1. Sharma A., Farouk I.A., Lal S.K. COVID-19: A Review on the Novel Coronavirus Disease. [(accessed on 14 May 2022)];Viruses. 2021 13:1–25. doi: 10.3390/v13020202. Available online: https://www.mdpi.com/1999-4915/13/2/202. - DOI - PMC - PubMed

LinkOut - more resources